Oncolytic virus therapy for resistant tumors

Patent metadata

Field	Value
Publication number	US-9862932-B2
Application number	US-201314416754-A
Country	US
Kind code	B2
Filing date	Mar 15, 2013
Priority date	Jul 24, 2012
Publication date	Jan 9, 2018
Grant date	Jan 9, 2018

Abstract

Disclosed herein is a recombinant oncolytic virus comprising a nucleic acid sequence encoding tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). One such oncolytic virus is oHSV. One form of TRAIL contained within the oncolytic virus is a secreted form of TRAIL. Examples of various forms of oHSV and secreted TRAIL are disclosed therein. Also disclosed are host cells and therapeutic formulations comprising the recombinant oncolytic virus. Also disclosed are methods of treating cancer in a subject by administering a therapeutic formulation comprising the recombinant oncolytic virus to the subject.

First claim

We claim:

1. A recombinant oncolytic herpes simplex virus (oHSV) comprising a nucleic acid sequence encoding, in expressible form, a polypeptide comprising the extracellular domain of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) fused to an isoleucine zipper and the extracellular domain of hFlt3 ligand, wherein the oHSV is selected from the group consisting of G47Δ, HSV-R3616, 1716, R3616, and R4009, and wherein the recombinant oncolytic herpes simplex virus induces apoptosis in tumor cells that are resistant to apoptosis induction by TRAIL and by oncolytic herpes simplex virus.

2. The recombinant oHSV of claim 1 , wherein the polypeptide encoded by said nucleic acid sequence is secreted by a cell infected by the recombinant oHSV.

3. The recombinant oHSV of claim 2 , wherein the expression of said polypeptide is regulated by the HSV immediate early 4/5 promoter.

4. The recombinant oHSV of claim 3 , wherein the virus contains an additional exogenous nucleic acid in expressible form.

5. The recombinant oHSV of claim 1 wherein the virus contains no additional exogenous nucleic acids.

6. A pharmaceutical composition comprising a recombinant oncolytic herpes simplex virus (oHSV) comprising a nucleic acid sequence encoding, in expressible form, a polypeptide comprising the extracellular domain of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) fused to an isoleucine zipper and the extracellular domain of hFlt3 ligand, and a pharmaceutically acceptable carrier, wherein the oHSV is selected from the group consisting of G47Δ, HSV-R3616, 1716, R3616, and R4009, and wherein the recombinant oncolytic herpes simplex virus induces apoptosis in tumor cells that are resistant to apoptosis induction by TRAIL and by oncolytic herpes simplex virus.

7. The pharmaceutical composition of claim 6 , wherein the polypeptide encoded by said nucleic acid sequence is secreted by a cell infected by the recombinant oHSV.

8. The pharmaceutical composition of claim 7 , wherein the expression of said polypeptide is regulated by the HSV immediate early 4/5 promoter.

9. The pharmaceutical composition of claim 6 wherein the virus contains no additional exogenous nucleic acids.

10. The pharmaceutical composition of claim 6 which is formulated for delivery to the brain.

Assignees

• Massachusetts Gen Hospital

Inventors

• Shah Khalid
• Tamura Kaoru
• Wakimoto Hiroaki

Classifications

• C07K14/525 Primary

  Tumour necrosis factor [TNF] · CPC title

• A61K35/763

  Herpes virus · CPC title

• C12N2710/16632

  Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent · CPC title

• C12N2710/16671

  Demonstrated in vivo effect · CPC title

• A61P35/00

  Antineoplastic agents · CPC title